Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice by Klocke, J. et al.
1Scientific RepoRts |          (2019) 9:8993  | https://doi.org/10.1038/s41598-019-45299-5
www.nature.com/scientificreports
prophylactic inhibition of soluble 
epoxide hydrolase delays onset of 
nephritis and ameliorates kidney 
damage in NZB/W F1 mice
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Epoxy-fatty-acids (EpFAs), cytochrome P450 dependent arachidonic acid derivatives, have been 
suggested to have anti-inflammatory properties, though their effects on autoimmune diseases like 
systemic lupus erythematosus (SLE) have yet to be investigated. We assessed the influence of EpFAs 
and their metabolites in lupus prone NZB/W F1 mice by pharmacological inhibition of soluble epoxide 
hydrolase (sEH, EPHX2). The sEH inhibitor 1770 was administered to lupus prone NZB/W F1 mice in a 
prophylactic and a therapeutic setting. Prophylactic inhibition of sEH significantly improved survival 
and reduced proteinuria. By contrast, sEH inhibitor-treated nephritic mice had no survival benefit; 
however, histological changes were reduced when compared to controls. In humans, urinary EpFA levels 
were significantly different in 47 SLE patients when compared to 10 healthy controls. Gene expression 
of EPHX2 was significantly reduced in the kidneys of both NZB/W F1 mice and lupus nephritis (LN) 
patients. Correlation of EpFAs with SLE disease activity and reduced renal EPHX gene expression in LN 
suggest roles for these components in human disease.
Arachidonic acid (AA) has several pathways of metabolism. The cyclooxygenase (COX) dependent prostaglan-
dins and the lipoxygenase (LOX) dependent leukotrienes are key variables in current treatment strategies con-
cerning inflammation and pain; however, another group of cytochrome P450 (CYP) dependent AA derivatives, 
the epoxy fatty acids (EpFAs), are relatively uncharacterised.
Epoxyeicosatrienoic acids (EETs) are products of CYP epoxygenases, while other CYP enzymes with hydrox-
ylase activity, and to some extent also LOX, lead to the production of hydroxyeicosatetraenoic acids (HETEs)1. 
EpFAs such as EETs are relatively short-lived and quickly metabolised by soluble epoxide hydrolase (sEH) and 
microsomal EH (mEH), to their less active diols, dihydroxyeicosatrienoic acids (DHETs). EETs are known to have 
anti-inflammatory and vasodilatory properties, which are opposed by the vasoconstriction and pro-inflammatory 
features of HETEs2–4. For a schematic overview of epoxide metabolism see Supplementary Fig. 1.
Manipulation of this anti-/proinflammatory equilibrium has been achieved by inhibition/knock-out of sEH 
and HETE-production with varying results. While an anti-inflammatory effect of EETs was suggested by reduced 
activation of NF-kB and consecutive downregulation of various pro-inflammatory cytokines and cell adhesion 
molecules, such as vascular cell adhesion protein 1 (VCAM1) on endothelial cells5,6, other studies also found 
an antihypertensive effect mediated by NO-release and enhanced natriuresis1,7–9. Further research hints at an 
improved outcome for cardiac10,11 and cerebral12 ischemia, and hypoxic pulmonary vasoconstriction13.
In the kidney, sEH inhibition has also been proposed as protective14,15. This effect might be due to an impair-
ment of monocyte chemoattractant protein 1 (MCP-1) driven chemotaxis in the absence of DHETs16. However, 
other data indicate that sEH knock-out results in aggravated chronic and acute kidney insufficiency, due to locally 
increased HETE concentrations through a negative feedback loop17,18. Consistent with this, HETE inhibition led 
to ameliorated acute renal failure in a rat model19.
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The broad efficacy in multiple disease models from increasing endogenous levels of EpFA, through blocking 
their metabolism by soluble epoxide hydrolase, has been difficult to explain1. A recent series of studies argued that 
an axis of mitochondrial dysfunction generating high reactive oxygen species acts through the endoplasmic retic-
ulum stress pathway to initiate a variety of pathological outcomes. EETs, and thus sEH inhibitors (sEHI), seem to 
disrupt this chain of events, leading to a variety of illnesses including chronic pain and diabetes20–23.
The role of EpFAs in chronic inflammatory and autoimmune diseases like systemic lupus erythematosus (SLE) 
has yet to be investigated. In this study, we assessed the influence of EpFAs and their metabolites in human SLE 
and especially LN, by measuring serum and urine concentrations of a wide panel of EETs and similar epoxides 
and their metabolites, as well as HETEs (see Supplementary Fig. 1 for a full list of all measured metabolites). In 
addition, sEH inhibitor 1770 was administered to NZB/W F1 mice, in both a prophylactic and a therapeutic set-
ting, to investigate the potential benefit of increasing certain bioactive lipids in lupus.
Results
EpFAs and sEH activity in the kidneys of lupus prone NZB/W F1 mice. To investigate the role 
of bioactive lipids in lupus, we analysed the concentrations of various CYP products and metabolites (see 
Supplementary Fig. 1 for a full list of metabolites) in the kidneys of lupus prone NZB/W F1 mice (n = 6, prene-
phritic NZB/W F1; n = 5, nephritic NZB/W F1) and the healthy C57BL/6NCRL (n = 7) mouse strain (cumulative 
data in Fig. 1; separated data in Supplementary Fig. 2). Kidneys of C57BL/6NCRL mice showed no significant 
change in any of the analysed metabolites with increasing age (n = 3 young versus n = 4 old; data not shown). For 
the NZB/W F1 comparison, young and old C57BL/6NCRL mice were presented as a combined cohort.
In the kidneys of NZB/W F1 mice before the onset of nephritis (prenephritic NZB/W F1), there was sig-
nificantly higher levels for the sum of all EETs (p = 0.0388, 1.5-fold increase, Fig. 1A) than in healthy Bl6 mice. 
In nephritic mice, the levels of the sum of all EETs (p = 0.0087) as well as 14,15-EET (p = 0.0087) and 8,9-EET 
(p = 0.0087) were comparable to those for Bl6 controls, and significantly lower than in prenephritic NZB/W F1 
mice. Similarly, epoxyoctadecenoic acids (EpOMEs) 8,9-EpOME (p = 0.0173) and 12,13-EpOME (p = 0.0087) 
concentrations in nephritic mice were lower when compared to prenephritic mice (Supplementary Fig. 2C). 
These changes between groups might at first glance indicate lower renal sEH activity in prenephritic mice.
Appropriately, a significantly lower sEH activity was found in the kidney of prenephritic NZB/W F1 mice 
(p = 0.0015), and even more so in nephritic mice (p = 0.0002), compared to Bl6 mice, as measured in an extended 
cohort (n = 7 prenephritic, n = 7 nephritic NZB/W F1, n = 12 Bl6; Fig. 1B). However, unexpectedly, the DHETs 
produced by sEH weren’t reduced in prenephritic mice, but were similarly enriched. The sum of all DHETs was 
Figure 1. Renal epoxy fatty acids and metabolites in lupus prone NZB/W F1 and healthy C57BL/6NCRL mice. 
(A) Comparison of the cumulative renal EET (5,6-; 8,9-; 11,12-; 14,15-EET), EpOME (9,10-; 12,13-EpOME), 
DHET (5,6-; 8,9-; 11,12-; 14,15-DHET), DiHOME (9,10-; 12,13-DiHOME) and 20-HETE levels between 
healthy C57BL/6NCRL (n = 7), prenephritic (n = 6) and nephritic NZB/W F1 mice (n = 5). (B) Renal sEH 
activity in healthy C57BL/6NCRL (n = 12), prenephritic (n = 7) and nephritic NZB/W F1 mice (n = 7). Bars, 
median; boxplots, median and interquartile range; whiskers, range; white boxplot, healthy C57BL/6NCRL 
mice; light grey boxplot, prenephritic NZB/W F1 mice; grey boxplot, nephritic NZB/W F1 mice; *p < 0.05; 
**p < 0.01; ***p < 0.001. Values that passed the Kolmogorov-Smirnov test for Gaussian distribution were 
compared using the unpaired t test; otherwise, the Mann-Whitney test was applied.
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higher (p = 0.0004) in prenephritic mice when compared to the C57BL/6NCRL controls and nephritic NZB/W 
F1 mice (p = 0.0087; Fig. 1A), mostly due to an increase in 5,6-DHET (Supplementary Fig. 2B). The sum of all 
sEH-produced dihydroxyoctadecenoic acids (DiHOMEs; p = 0.0097) was decreased in the prenephritic group.
sEH Inhibition delayed onset of nephritis and improved survival in prenephritic NZB/W F1. The 
sEH inhibitor 1770 (sEHI) was administered to NZB/W F1 mice to investigate the potential benefit of increased 
bioactive lipids in lupus. NZB/W F1 mice aged five months, without any signs of nephritis (no proteinuria), were 
either treated with sEHI or just the PEG co-solvent in their drinking water for 4 weeks (Fig. 2). Administration 
of sEHI in this prophylactic setting, before the onset of nephritis, significantly improved survival (n = 10 sEHI 
group, n = 11 PEG group; p = 0.0478 log-rank test). Consistent with the improved survival, reduced proteinuria 
was observed in the sEHI treated group (ANOVA p < 0.0001; Fig. 2A).
In a second clinical setting, sEHI was administered to mice with overt nephritis (proteinuria ≥ 300 mg/dl, 
median age 25.6 weeks) for 3 weeks, to test whether sEH inhibition was also able to influence established disease. 
Exposure was limited to 3 weeks, to avoid loss of animal due to the underlying lupus disease. In this therapeu-
tic setting, no significant impact on survival was detectable (n = 11 in each group, experimental and control; 
p = 0.1379; Fig. 2B). In addition, no significant change in proteinuria was observed (data not shown).
At the beginning of treatment, prenephritic mice had significantly less anti-dsDNA-antibodies (mean 
203 µg/ml) and proteinuria (mean 0 mg/dl) than nephritic mice (mean 360 µg/ml and 300 mg/dl, respectively; 
p < 0.0001). Treatment with sEHI had no significant influence on levels of dsDNA antibodies (data not shown).
Treatment with sEHI ameliorated kidney damage. Kidney samples were analysed for severity of 
nephritis, to assess the impact of sEH-inhibition on kidney damage. Prenephritic mice were sacrificed after four 
weeks of exposure to either sEHI or PEG (Fig. 3). As expected, no histological differences were observed between 
the sEHI and PEG groups (n = 5 in each group; Fig. 3A,B). In nephritic mice, typical histological features of 
proliferative Lupus nephritis were obvious (Fig. 3C,D), and were scored using the Austin activity and chronicity 
index24. In nephritic mice treated for three weeks with sEHI, ameliorated kidney damage was observed in the 
form of a significantly lower activity index compared to the control group (p = 0.0391; Fig. 3E), while the index 
for chronic changes was unchanged between the two groups (n = 8 in each group; Fig. 3F). Of the histologic 
features assessed, a significant reduction in cellular crescents (p = 0.0451) and hyaline deposits (p = 0.0015) was 
found (data not shown).
Figure 2. Impact of sEH inhibitor 1770 on the survival and proteinuria of NZB/W F1 mice. Survival of NZB/W 
F1 mice in a prophylactic (A) and a therapeutic (B) setting. Mice were treated with sEH inhibitor 1770 in 
1% PEG400 (grey) or just 1% PEG400 (black). Each treatment included n = 11, except for prophylactic sEHI 
(n = 10); ***p < 0.001. Proteinuria comparison in the prophylactic setting. (C) Differences were measured 
using the log-rank test.
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sEH inhibition induced significant changes in the renal bioactive lipid profile. To monitor both 
systemic and renal changes, a broad panel of bioactive lipids (see Supplementary Fig. 1) were assayed in the kid-
neys and spleens of NZB/W F1 mice exposed to sEHI in the prophylactic and therapeutic setting (Fig. 4). While 
there was no direct change in the epoxide fatty acids (EETs and EpOMES) between the treatment and control 
groups, the administration of sEHI significantly altered the concentrations of their respective diol-metabolites 
(DHETs and DiHOMEs). In the spleens of prophylactically treated mice, sEHI significantly increased the levels 
of 14,15-DHET (p = 0.0240) and 8,9-DHET (p = 0.0430; n = 5 in each group). In the kidneys, sEH inhibition in 
the prophylactic group increased levels of 11,12-DHET (p = 0.006), 8,9- DHET (p = 0.0360), 12,13-DiHOME 
(p = 0.0170) and overall DiHOME (p = 0.0500; n = 10 sEHi group, n = 11 PEG group).
By contrast, in a therapeutic setting, NZB/W F1 mice treated with sEHI showed a decrease in renal 
9,10-DiHOME (p = 0.0150; n = 8 in each group) and splenic 12,13-DiHOME (p = 0.0230; n = 3 in each group) 
compared to the control group. A significant increase in splenic levels of 20-HETE also occurred in the therapeu-
tic setting (p = 0.0300).
To further investigate the effect of the altered bioactive lipid profiles on immune responses, a panel of 
cytokines, interleukin (IL)-1 α, IL-2, IL-5, IL-21, IL-6, IL-10, interferon gamma (IFN γ), tumor necrosis factor 
alpha (TNF α), IL-4, IL-17 and granulocyte-macrophage colony-stimulating factor (GM-CSF) were measured in 
Figure 3. Impact of therapeutic sEH inhibition on renal histology findings in lupus prone NZB/W F1 mice. 
Representative kidney histology in the prophylactic group after four weeks of exposure to PEG (A) or sEHI 
(B; HE staining, 200x magnification). (C) Example histology from the treatment group after three weeks of 
exposure to PEG. Note the destroyed glomeruli (PAS staining, 200x magnification). (D) Kidney sample after 
3-weeks exposure to sEHI, showing less severe glomerular changes than for the PEG group (PAS staining, 
200x magnification). Scale bars = 100 µm. Comparison of the activity (E) and chronicity (F) indices of kidneys 
after three weeks of sEHI (n = 8) and PEG treatment (n = 8) of mice in the therapeutic setting. Boxplots show 
medians and interquartile ranges; whiskers, range; light grey, PEG treatment; dark grey, sEHI treatment; 
*p < 0.05. Compared using Mann Whitney test.
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plasma for the prophylactic and the therapeutic settings. In addition, spleens were removed and analysed as a 
major immunologic organ, where dysregulation of several immune subsets can be monitored. Splenic T cell sub-
sets, B cells and plasma cells of prenephritic mice were monitored by flow cytometry after four weeks of treatment 
with either sEHi or PEG (Supplementary Fig. 3). Regarding cytokines, only GM-CSF levels were significantly 
decreased by prophylactic sEH inhibition (p = 0.0208; n = 5 for each group; Supplementary Fig. 3A), when com-
pared to the control group. The increase in IL-5, IL-6, IFNg and TNFa between prophylactic and therapeutic 
groups was attributed to a general increase in inflammation due to a prolonged and unaltered course of disease. 
sEH inhibition did not significantly alter the monitored lymphocyte subsets (Supplementary Fig. 3B,C).
Differences in urinary EpFAs between SLE patients and healthy controls. In order to assess the 
potential implication of EpFAs and related bioactive lipids in SLE, the concentrations of lipid mediators (see 
Supplementary Fig. 1) were determined in serum and urine samples of 49 SLE patients (33 patients with acute or 
prior LN, and 16 patients without renal disease; Table 1). In addition, levels of urinary EpFAs were measured in 
10 healthy controls. The bioactive lipids were not significantly different between the SLE disease groups in either 
urine (Fig. 5) or serum (data not shown), although patients with renal disease showed some positive correlations 
between disease activity based on the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and vari-
ous urinary and serum EpFAs (data not shown).
By contrast, SLE patients had an altered urinary EpFA profile in comparison with healthy controls. In all 
SLE patients, urinary EET concentrations were already low; however, in the control group, EETs could not be 
detected at all (p < 0.0001; Fig. 5A). Paradoxically, the closely related epoxy lipids EpOMEs had slightly higher 
concentrations in the urine of healthy controls (p < 0.0001; Fig. 5D). In comparison, urinary concentrations of 
sEH produced dihydroxy lipids DHET and DiHOME were overall more pronounced, but did not differ between 
disease and control mice (Fig. 5B,E). Urinary 20-HETE tended to have a slightly higher concentration in healthy 
controls, albeit only when compared to SLE patients without renal disease (p = 0.0451; Fig. 5C).
Renal EPHX2 gene expression was reduced in NZB/W F1 mice and LN patients. We reviewed 
gene transcription data provided by Berthier et al. (GSE32591) via the Gene Expression Omnibus (GEO) data-
base25. The dataset contained renal gene expression profiles for 35 NZB/W F1 mice (GSE32583), 32 human LN 
patients and 15 living transplant donors as controls (GSE32591). The murine dataset contained NZB/W F1 mice 
Figure 4. Comparison of metabolic changes in sEHI- and PEG-treated NZB/W F1 mice in the kidneys 
and spleen. To visualise changes due to sEH inhibition, the values are displayed as ratios (sEHI group/PEG 
group); consequently, a ratio >1 indicates an increased amount of that metabolite, while a ratio <1 indicates a 
decreased amount, compared to the PEG group. Significant differences between groups are measured by Mann 
Whitney test and are indicated by asterisks. Light grey, prophylactic setting (4 weeks sEHI exposure before onset 
of proteinuria); dark grey, therapeutic setting (3 weeks sEHI exposure after onset of proteinuria); *p < 0.05; 
**p < 0.01.
SLE, LN SLE, no LN Healthy controls
n= 33 16 10
Female (%) 25 (76) 14 (88) 8 (80)
Age 37 (21─54) 48 (22─71) 31 (23─65)
SLEDAI 9 (0─25) 5 (0─15) —
Creatinine (mg/dl) 0.92 (0.47─2.01) 0.81 (0.63─0.97) 0.75 (0.58─0.83)
Proteinuria (mg/d) 1799 (142─6724) 127 (52─165) —
Table 1. Patient characteristics. Values are means (range); LN, patients with current or former lupus nephritis; 
SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.
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of varying age (16 weeks n = 8, 23 weeks n = 17, 36 weeks n = 10) and disease stage (prenephritic n = 19, nephritic 
n = 16). Older mice were generally sicker, with some 23 week-old and all 36 week-old mice being nephritic. 
Both age and disease status seemed to affect EPHX2 gene expression (encoding for sEH), with young mice hav-
ing higher gene expression than old mice (p = 0.0014), and prenephritic mice showing higher expression than 
nephritic mice (p = 0.0263; Fig. 6A). By contrast, EPHX1 expression (encoding for mEH) was not dependent on 
age or disease stage in NZB/W F1 mice.
In the human dataset, we also compared EPHX1 and EPHX2 gene expression between LN patients and con-
trols. Gene expression data were divided into interstitium and glomerular renal compartments (Fig. 6B). EPHX1 
expression was significantly reduced in LN patients in both renal compartments (p < 0.0001). While there was no 
difference in EPHX2 gene expression in the tubulointerstitium, in the glomeruli it was significantly reduced in 
acute LN patients when compared to healthy controls (p < 0.0001).
In addition, gene expression of EpFA producing CYP epoxygenases CYP2C19, CYP2C8, CYP2C9 and 
CYP2J2 were examined in the same human dataset (Supplementary Fig. 4). CYP2C8 (p = 0.0203) and CYP2C9 
(p < 0.0001) showed decreased tubulointerstitial gene activity in LN patients, thus potentially mirroring the 
decreased EET production in the murine model. CYP2C19 and CYP2J2 showed no difference between groups.
Discussion
In this study, we showed the impact of altering the bioactive lipid profile in lupus prone NZB/W F1 mice by inhi-
bition of sEH, and provided the first evidence that EpFAs and their metabolites might contribute to pathogenesis 
of human lupus nephritis. We collected observational data on three distinct levels (murine plasma and organ 
samples, human urine samples, murine and human renal gene expression), which all indicated a dysregulation 
in EpFA production and metabolisation in SLE and LN, although the results were not always consistent with the 
current understanding of EpFA metabolisation.
In the murine model (Fig. 1), a lower sEH activity was predictably associated with significantly elevated EET/
EpOME concentrations; however, the concurrent elevation of corresponding diol-metabolites DHET was not 
anticipated. This occurred in prenephritic NZB/W F1 mice only, and might indicate increased CYP-dependent 
EET production that could not be sustained as the disease progressed. Why alterations in lipid profile were more 
pronounced in this early phase of the disease remained unclear. Human urine samples (Fig. 5) substantiated 
the murine findings with EETs exclusively being detected in SLE patients, albeit with a paradoxical elevation of 
EpOME concentrations in healthy controls.
Figure 5. Urinary EpFA levels and metabolites in SLE patients and healthy controls. Bars, median; each dot 
represents one patient/one measurement; filled dots, LN patients; cross-hatched dots, SLE patients without renal 
disease; open dots, healthy controls. For a full list of all EpFAs measured in each group, see Supplementary Fig. 1 
and Supplementary Table 1. *p < 0.05; **p < 0.01; ***p < 0.001.
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Our survey of EPHX gene expression indicated renal downregulation of sEH with progressing disease in 
NZB/W F1 mice (Fig. 6A), and thus underlined the findings concerning renal sEH activity (Fig. 1B). Reduced 
sEH gene expression was also found in humans (Fig. 6B), where lower mEH and CYP epoxidase gene expression 
was observed in LN patients. The generally lower gene expression and sEH activity in lupus patients found in the 
current study might be explained by an accumulation of damaged tissue due to prolonged inflammation. Even so, 
overall, it remained unclear why inflammatory renal disease seemed to be associated with an intrinsic increase in 
anti-inflammatory lipids.
As our interventional data implied, altering the EpFA-signature in the prenephritic lupus prone mice by inhi-
bition of sEH led to a significant improvement of survival and a transient reduction of proteinuria (Fig. 2). This 
was supported by the lack of histological changes in the kidneys of these mice (Fig. 3). The same could not be 
achieved in NZB/W F1 mice that already displayed signs of nephritis. While the lack of a benefit in overall sur-
vival in these mice was disappointing from a clinical perspective, the histological findings at least suggested an 
amelioration of kidney damage; therefore, sEHI might still improve the overall disease course. These findings 
were consistent with previous reports on the effect of sEHI on kidney damage, ranging from diabetic nephropa-
thy26 to obstructive nephropathy27,28. More positive effects have recently been achieved by EET analogues in other 
disease models29–32. The improved outcome was mostly attributed to antihypertensive properties of the EETs; 
however, changes in inflammatory responses were also reported, such as reduced infiltration of neutrophils and 
macrophages28,32 and decreased interstitial fibrosis27.
To evaluate how sEH inhibition altered disease course in the current study, it was monitored on multiple 
levels. First, we observed changes in the profile of the bioactive lipids in both kidney and spleen. Interestingly, 
we detected no change in epoxy- fatty acids (EETs and EpOMEs), but only in their diol-metabolites (DHETs and 
DiHOMEs). We assumed that inhibition of sEH would lead to a reduction of DHETs and DiHOMEs, in com-
parison to the control group; however, this was only the case in the therapeutic setting, whereas prophylactically 
treated mice had significantly higher diol- concentrations than the controls. In the prophylactic setting, mice 
were treated over a longer timespan than their therapeutic counterparts, which might possibly have led to the 
activation of alternate metabolism pathways, such as mEH.
We also detected increased concentrations of the pro-inflammatory 20-HETE. Increased HETE after 
sEH-knockout has been attributed to a general shift in the metabolism of AAs towards the 20-HETE producing 
CYP-dependent pathway or the lipoxygenase pathways, which produce most other HETEs17–19. However, in this 
case it seemed more likely that the increased 20-HETE levels in the spleen were a result of prolonged inflamma-
tion, not sEH inhibition, as they were only detected in the therapeutic setting.
No significant changes in the initial immune response after sEHI treatment were found on measurement of 
cytokines, except for an increased GM-CSF concentration. However, due to the exploratory nature of the current 
study no correction for multiple testing was done. Consequently, in the absence of any other immunological 
changes, the validity of these findings was unclear. Cytokines were only detected in plasma; therefore, there might 
be renal changes that were not apparent in our data. The same conclusions could also be made for our monitoring 
of cellular immune responses, where we did not see any differences in splenic T cell and B cell subsets between 
groups.
Figure 6. Renal mEH (EPHX1) and sEH (EPHX2) gene expression in NZB/W F1 mice and human LN 
patients and controls. (A) Renal EPHX gene expression in NZB/W F1 mice with increasing age and disease. 
Bars, median; every circle represents one value; filled circles, nephritic mice; open circles, prenephritic mice, 
*p < 0.05 (when comparing n = 11 prenephritic 23 week old mice with n = 10 nephritic 36 week old mice), 
**p < 0.01. (B) Comparison of renal EPHX expression in the tubulointerstitium and glomeruli of 32 patients 
with acute LN and 15 healthy pre-transplant donors. Bars, median; every circle represents one patient/value; 
filled circles, LN patients; open circles, controls; ****p < 0.0001. Values that passed the Kolmogorov-Smirnov 
test for Gaussian distribution were compared using the unpaired t test; otherwise, the Mann-Whitney test was 
applied.
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Pharmacological inhibition of sEH with sEHI 1770 improved survival and proteinuria of lupus prone NZB/W 
F1 mice in a prophylactic treatment setting. Although the inhibition altered the bioactive lipid profile, the under-
lying immunologic mechanisms have yet to be determined. Reduced renal sEH gene expression in both murine 
and human settings, as well as alterations in the urinary lipid profile of SLE patients compared to healthy controls, 
suggested a role of bioactive lipids in human lupus disease.
Methods
Animals. C57BL/6NCRL and lupus prone NZB/W F1 (NZB × NZW F1) mice were obtained from the 
Bundesinstitut für Risikobewertung in Marienfelde, Berlin, Germany. Female mice were kept in a specific path-
ogen-free environment at the German Rheumatology Research Centre (DRFZ, Berlin, Germany. Standard chow 
and water were offered ad libitum. Experiments were performed in accordance with National Institutes of Health 
Guidelines on the Use of Laboratory Animals. The Animal Care Committee of the Charité University, Berlin 
approved the experiments (approval number G0003/11).
Determination of sEH activities. Renal cytosolic fractions were prepared as described previously33. The 
assay was performed at 37 °C for 20 min in a final volume of 100 μL 0.1 M potassium phosphate buffer pH 7.2 
containing 50 μM 14,15-EET as substrate. The reactions were started by adding the cytosolic fraction (3.5 μg of 
protein), and were terminated with 300 μl ethyl acetate. The remaining substrate and its product (14,15-DHET) 
were extracted and analysed by reversed-phase high performance liquid chromatography (RP-HPLC)33.
Measurement of splenic and renal EpFA concentrations and renal sEH activity. Splenic and 
renal EpFA concentrations were measured with a Lipidomix kit (Lipidomix GmbH, Berlin, Germany) in healthy 
C57BL/6NCRL mice aged 2 months and 14 months, as well as in prenephritic (aged 2 months) and nephritic 
(aged 6 months) lupus prone NZB/W F1 mice. Tissue samples were homogenised in liquid nitrogen and aliquots 
corresponding to 30 mg wet weight were used for oxylipin analysis.
Sample preparation and analysis of polyunsaturated fatty acid-derived lipid mediators and 
metabolites. Homogenised tissues from the animal experiments were spiked with an internal standard con-
taining 10 ng of each of 14,15-EET-d8, 14,15-DHET-d11, 15-HETE-d8, 20-HETE-d6, LTB4-d4 and PGE2-d2 
(Cayman Chemical, Ann Arbor, USA). In addition, 500 µl methanol and 300 µl 10 M sodium hydroxide solution 
was added to the tissue and it was shaken vigorously and heated for 30 min at 60 °C for alkaline hydrolysis. The 
samples were then brought to pH 6 with 500 µl 1 M sodium acetate buffer and acetic acid. After centrifugation, 
the supernatant was added to a Bond Elute Certify II column (Agilent Technologies, Santa Clara, USA) for solid 
phase extraction (SPE). The columns were preconditioned with 3 ml methanol, followed by 3 ml 0.1 mol/l sodium 
acetate buffer containing 5% methanol (pH 6). The SPE-columns were then washed with 3 ml methanol/H2O 
(50:50, vol:vol). For elution 2 ml n-hexane:ethyl acetate (25:75) with 1% acetic acid was used. The extraction was 
performed with a SPE vacuum manifold. The eluate was evaporated on a heating block at 40 °C under a stream of 
nitrogen, to obtain a solid residue. The residues were dissolved in 70 µL acetonitrile and analysed using an Agilent 
1200 HPLC system (Agilent Technologies, Santa Clara, USA) with binary pump, degasser, autosampler and col-
umn thermostat, with a Kinetex C-18, 2.1 × 150 mm, 2.6 µm column (Phenomenex, Aschaffenburg, Germany), 
using a solvent system of 0.1% aqueous formic acid and acetonitrile. The elution gradient was started with 5% 
acetonitrile, which was increased within 0.5 minutes to 55%, 14.5 minutes to 69%, 14.6 minutes to 95% and held 
there for 5.4 minutes. The flow rate was set at 0.3 ml/min, and the injection volume was 7.5 µl. The HPLC was 
coupled to an Agilent 6460 Triplequad mass spectrometer (Agilent Technologies, Santa Clara, USA), with an 
electrospray ionisation source. The source parameters were: drying gas, 250 °C/10 l/min; sheath gas, 400 °C/10 l/
min; capillary voltage, 4500 V; nozzle voltage, 1500 V; and nebulizer pressure, 30 psi. Analysis was performed with 
multiple reaction monitoring in negative mode. For further details see Arnold et al.34.
Treatment with sEHI 1770. Prenephritic and nephritic NZB/W F1 mice were provided with the 
1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU; sEHI 1770)1,35 dissolved in drinking water. 
NZB/W F1 mice aged five months, without any signs of nephritis (no proteinuria), were treated with sEHI orally 
(n = 10). The solution for dosing was generated by adding 3.5 mg TPPU dissolved in 5 ml PEG400 to 500 ml 
warm drinking water with stirring, to give a final concentration of 7 mg/l TPPU, equalling a dose of 1 mg/kg/day. 
Control animals were treated with the PEG400 solvent alone (n = 11). Treatment resulted in mean blood con-
centrations of 2.396 nM and 2.027 nM after one and two weeks of treatment, respectively, indicating TPPU was 
at near steady state levels. The concentrations were comparable to those in previous TPPU studies36. In a second 
experimental setting, oral administration of sEHI in PEG400 solvent (n = 11) or PEG400 alone (n = 11) was ini-
tiated in mice with overt nephritis (proteinuria ≥300 mg/dl, median age 25.6 weeks). Proteinuria was measured 
using Multistix reagent strips (Bayer Diagnostics, Germany).
Histological analysis. Prenephritic mice were sacrificed after four weeks of exposure to PEG + sEHI or 
to PEG. Nephritic mice were treated for three weeks after the onset of nephritis with PEG + sEHI or PEG. In 
the prophylactic setting, mice were treated for four weeks before analysis; however, in the treatment setting the 
exposure was limited to three weeks, to avoid loss of animals due to the underlying lupus disease. Kidneys were 
removed and fixed with 2% paraformaldehyde. The samples were paraffin embedded, cut in sections and stained 
with haematoxylin/eosin (HE) and periodic acid-Schiff (PAS) reagents. Slides were examined by experienced 
pathologists blinded to the treatment conditions; typical histological features of LN were determined and scored 
using the Austin activity and chronicity index24.
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Additional analysis. Splenic cells and plasma cytokines were measured by flow cytometry and multiplex 
assays, respectively, in prenephritic and nephritic NZB/W F1 mice (Supplementary Fig. 3).
For flow cytometry, a cell suspension of freshly removed spleens (removed concurrently with the kidneys) 
was generated by dissipating and straining through a 70 µm cell strainer. Cells were permeabilised using the Fix 
& Perm Cell Permeabilization Kit (Invitrogen, Frederick, MD, USA). To block non-specific binding, cells were 
stained in phosphate-buffered saline with 1% bovine serum albumin containing 10% human immunoglobulin 
G (IgG; Flebogamma, Grifols, Langen, Germany). Staining was performed for 20 minutes at 4 °C with CD3-PE, 
CD8-Cy5, CD19-PB, CD44PB, (all DRFZ, Berlin, Germany), CD138-PE, Ki67-PECy7 (both BD, Franklin Lakes, 
New Jersey, USA), CD4-PerCP, CD69-FITC, and FoxP3-APC (all eBioscience, San Diego, California, USA). To 
exclude dead cells, phycoerythrin (DRFZ, Berlin, Germany) was added immediately before flow cytometry. The 
samples were measured using a MACS Quant Analyzer (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). 
After exclusion of doublets and dead cells, T cells were gated by CD3 expression and B cells were gated by CD19 
expression. Further subtyping was achieved with the markers given above. Datasets were analysed using Flowjo 
Software (Tree Star, Ashland, Oregon, USA).
Additionally, a panel of cytokines (IL-1α, IL-2, IL-5, IL-21, IL-6, IL-10, IFN-γ, TNF-α, GM-CSF, IL-4 and 
IL-17) was assessed in thawed serum samples, stored at −80 °C. A Flowcytomix multiplex assay kit (eBioscience, 
San Diego, California, USA) was used according to the standard procedure suggested by the supplier.
patients. Serum and urine samples of 47 SLE patients and 10 healthy controls were analysed for a wide array 
of lipid mediators: 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET, 9,10-EpOME, 12,13-EpOME, 5,6-DHET, 8,9-DHET, 
11,12-DHET, 14,15-DHET, 9,10-DiHOME, 12,13-DiHOME, 19-HETE, 20-HETE, and the sum of all EETs, 
EpOMEs, DHETs, DiHOMEs and HETEs. We collected and stored 49 serum and urine samples from 47 patients 
with SLE between 2009 and 2012. The samples were analysed in 2012. Two patients were evaluated twice with 
at least two years between measurements. Samples from healthy controls were collected and analysed in 2019.
SLE patients were divided into two groups based on their renal involvement, “SLE, LN” and “SLE, no LN.” 
The SLEDAI was calculated for all patients. Thirty-three patients had LN, as determined by at least one positive 
biopsy for current LN (n = 16) or during a prior course of the disease (n = 17). The remaining 16 patients had no 
diagnosed LN (see Table 1 for patient characteristics). Samples were collected from patients of the Departments 
of Rheumatology and Clinical Immunology, and Nephrology, Charité University Hospital, Berlin, Germany. The 
ethics committee of Charité University Hospital (Charité EA1/034/10) approved the study, and the investigation 
was carried out in compliance with the Declaration of Helsinki. Informed consent was obtained from all patients 
before participation.
serum and urinary epFAs in sLe patients. Serum and urine samples were collected and immediately 
centrifuged, with the resulting supernatant being stored at −80 °C. Frozen samples were analysed as detailed 
above.
Gene transcription data. The gene expression profile GSE32592 from the GEO database was down-
loaded37, and the gene expression of EPHX1 (mEH) and EPHX2 (sEH) was reviewed. In their original work on 
this dataset, Berthier et al. identified renal transcription features common in human LN and murine LN models25. 
The series contained gene transcription profiles of glomeruli and the tubulointerstitium of 32 LN patients and 
15 controls represented by pre-transplant healthy living donors (GSE32591, for further patient information see 
Berthier et al.25). It also included profiles of 35 NZB/W F1 mice with varying ages and disease stages (GSE32583).
statistical analysis. Datasets that passed the Kolmogorov-Smirnov test for Gaussian distribution were 
compared using the unpaired t test/one way analysis of variance (ANOVA); otherwise, the Mann-Whitney test/
Kruskal-Wallis test was applied. Significances between individual groups were calculated by t-test/Mann-Whitney 
test. For comparisons of three groups, those with statistically significant differences also passed the one way 
ANOVA or Kruskal-Wallis test. Correlations were calculated by Spearman correlation. Survival was calculated 
by log-rank test. All medians, means, ANOVA tests, Kruskal-Wallis tests, unpaired t-tests, Mann–Whitney 
tests, Spearman correlations and log-rank tests were calculated using GraphPad Prism 7 software (GraphPad 
Software, San Diego, California, USA). Due to the explorative nature of the study, we did not control for multiple 
comparisons.
Ethical approval and consent to participate. Experiments were performed in accordance with the 
National Institutes of Health Guidelines on the Use of Laboratory Animals. The Animal Care Committee of 
Charité University Berlin approved the experiments (approval number G0003/11). The ethics committee of 
Charité University Hospital (Charité EA1/034/10) also approved the study, and the investigation was carried 
out in compliance with the Declaration of Helsinki. Informed consent was obtained from all patients before 
participation.
Data Availability
The datasets generated and/or analysed during the current study are available from the corresponding author by 
request.
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